Abstract

You have accessJournal of UrologyBladder Cancer: Basic Research (I)1 Apr 2013581 HUMAN β DEFENSIN-2 MAY INHIBIT INTERNALIZATION OF BACILLUS CALMETTE-GUE′RIN IN BLADDER CANCER CELLS Sang Hyup Lee, Jae Dong Chung, Jung Hoon Kim, In Ho Chang, Tae-Hyoung Kim, Soon Chul Myung, Young Tae Moon, Kyung Do Kim, Seung Hyun Ahn, and Yong Seong Lee Sang Hyup LeeSang Hyup Lee Seoul, Korea, Republic of More articles by this author , Jae Dong ChungJae Dong Chung Seoul, Korea, Republic of More articles by this author , Jung Hoon KimJung Hoon Kim Seoul, Korea, Republic of More articles by this author , In Ho ChangIn Ho Chang Seoul, Korea, Republic of More articles by this author , Tae-Hyoung KimTae-Hyoung Kim Seoul, Korea, Republic of More articles by this author , Soon Chul MyungSoon Chul Myung Seoul, Korea, Republic of More articles by this author , Young Tae MoonYoung Tae Moon Seoul, Korea, Republic of More articles by this author , Kyung Do KimKyung Do Kim Seoul, Korea, Republic of More articles by this author , Seung Hyun AhnSeung Hyun Ahn Seoul, Korea, Republic of More articles by this author , and Yong Seong LeeYong Seong Lee Seoul, Korea, Republic of More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.02.1977AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES To investigated whether secretion of human β defensin (HBD)-2 is induced by Bacillus Calmette-Gue′rin (BCG) and HBD-2 affects BCG internalization into bladder cancer cells. METHODS Reverse transcription-polymerase chain reaction analysis was performed to determine whether HBD-2 mRNA increased by incubation with BCG, and HBD-2 proteins in 5637 and T24 human bladder cancer cell lines were assayed by enzyme-linked immunosorbent assay. To test the optimal dose of HBD-2 on BCG internalization, the internalization rate was evaluated by double immunofluorescence assay and confocal microscopy. We also investigated the difference in internalization rates between recombinant HBD-2 protein, anti-HBD-2 antibody, and HBD-2 plus anti-HBD-2 antibody pretreatments. RESULTS BCG induced HBD-2 mRNA expression and HBD-2 production dose and time-dependently in bladder cancer cells. Pre-treatment with recombinant HBD-2 protein lowered internalization of BCG dose-dependently. Moreover, Anti-HBD-2 antibody prevented the effect of HBD-2 on internalization of BCG in bladder cancer cells. The internalization rate of BCG pretreated with anti-HBD-2 antibody was higher than that in the control in 5637 (p < 0.01) and T24 cells (p < 0.05). The BCG internalization rate in cells pretreated with anti-HBD-2 antibody plus recombinant HBD-2 protein was higher than that in the control in 5637 (p < 0.01) and T24 cells (p < 0.05). CONCLUSIONS Bladder cancer cells produce HBD-2 when they are infected by BCG to defend themselves against BCG internalization, which plays an important role during the initiation and propagation of the immunotherapeutic response in bladder cancer cells. © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 189Issue 4SApril 2013Page: e238 Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.MetricsAuthor Information Sang Hyup Lee Seoul, Korea, Republic of More articles by this author Jae Dong Chung Seoul, Korea, Republic of More articles by this author Jung Hoon Kim Seoul, Korea, Republic of More articles by this author In Ho Chang Seoul, Korea, Republic of More articles by this author Tae-Hyoung Kim Seoul, Korea, Republic of More articles by this author Soon Chul Myung Seoul, Korea, Republic of More articles by this author Young Tae Moon Seoul, Korea, Republic of More articles by this author Kyung Do Kim Seoul, Korea, Republic of More articles by this author Seung Hyun Ahn Seoul, Korea, Republic of More articles by this author Yong Seong Lee Seoul, Korea, Republic of More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.